Clinical practice guidelines for BRCA1 and BRCA2 genetic testing

Pujol, Pascal; Barberis, Massimo; Beer, Philp; Friedman, Eitan; M. Piulats, Josep; Capoluongo, Ettore; García‐Foncillas, Jesús; Ray‐Coquard, Isabelle; Penault‐Llorca, Frédérique; D. Foulkes, William; Turnbull, Clare; Hanson, Helen; A. Narod, Steven; Arun, Banu; Aapro, Matti; Mandel, Jean‐Louis; Normanno, Nicola; Lambrechts, Diether; Vergote, Ignace; Anahory, Michèle; Baertschi, Bernard; Baudry, Karen; Bignon, Yves–Jean; A. Bollet, Marc; Corsini, Carole; Cussenot, Olivier; De La Motte Rouge, Thibault; Duboys de Labarre, Marie; Duchamp, Florence; Duriez, Clarisse; Fizazi, Karim; Galibert, Virginie; Gladieff, Laurence; Gligorov, Joseph; Hammel, Pascal; Imbert‐Bouteille, Marion; Jacot, William; Kogut-Kubiak, Tatiana; Lamy, Pierre‐Jean; Nambot, Sophie; Neuzillet, Y.; Olschwang, Sylviane; Rébillard, Xavier; Rey, Jean‐Marc; Rideau, Chloé; Spano, Jean-Philippe; Thomas, Frédéric; Treilleux, Isabelle; Vandromme, Marion; A. Vendrell, Julie; Vintraud, Michèle; Zarca, D.; S. Hughes, Kevin; Enrique Alés Martínez, Jose

doi:10.1016/j.ejca.2020.12.023

Public

Clinical practice guidelines for BRCA1 and BRCA2 genetic testing

Published in European Journal of Cancer • Feb 10, 2021

Authors:

Pascal Pujol

Massimo Barberis

Philp Beer

Abstract

BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-related cancer. Because issues of BRCA testing in clinical practice now overlap with both preventive and therapeutic manage...

Subject

Medicine

Genetic testing

Breast cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!